William Abramovits, MD
Dermatology · Dallas, TXNPI 1154379188
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $223,208 of the $325,267 with a category attached, or 68.6%. It is spread thinly across 50 manufacturers, the largest accounting for just 20.7%. Reporting peaked in 2019 at $122,501 and has fallen 86.9% since, to $16,009 in 2025. Among dermatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,542 payments — averaging $210.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$67K
- Sun Pharmaceutical Industries Inc.$55K
- Sanofi$31K
- Regeneron Healthcare Solutions, Inc.$30K
- LEO Pharma Inc.$25K
- Novartis$23K
- plus $93K from 44 others
Across 335 payments — averaging $4595.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$585K
- Kyowa Kirin Pharmaceutical Development, Inc$326K
- Boehringer Ingelheim$135K
- Eli Lilly$100K
- Pfizer$75K
- Vanda Pharmaceuticals Inc.$71K
- plus $248K from 16 others
What the payments were for
- Consulting fees$40,66613%
- Speaking & faculty fees$223,20869%
- Travel & lodging$16,6685%
- Food & beverage$43,86013%
- Education$8650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$325,267 in reported general payments places this provider in the 95th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 14 | $1,278 |
| Ciclopirox | 11 | $288 |
| Terbinafine Hcl | 13 | $255 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$1.3M
- Ross RaduskyDallas$1.2M
- Joseph MerolaDallas$1.2M
- So Yeon PaekDallas$812K
- Martin MenterDallas$512K
- Mary HornerDallas$448K
- Donald GlassDallas$347K
- Mary FleischliDallas$153K
- Adean KingstonDallas$141K
- Edward LainAustin$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.